Finerenone Slows CKD Progression in Type 2 Diabetes

FIDELIO-DKD establishes the nonsteroidal mineralocorticoid receptor antagonist finerenone as a distinct cardiorenal-protective agent layered on maximally tolerated renin-angiotensin system blockade in diabetic kidney disease.

finerenonemineralocorticoid receptor antagonistnonsteroidal MRAchronic kidney diseasetype 2 diabetesdiabetic kidney diseasehyperkalemiaFIDELIO-DKDrandomized controlled trialcardiorenal Nephrology / Renal Pharmacy

Background Information

Finerenone reduces kidney and cardiovascular risks in diabetes patients.

Managing chronic kidney disease (CKD) in type 2 diabetes can reduce progression and improve patient outcomes. Finerenone lowered the risk of CKD progression and cardiovascular events, with hazard ratios of 0.82 and 0.86 respectively, though more hyperkalemia was observed. Finerenone offers a beneficial option for CKD progression and cardiovascular protection in type 2 diabetes, though hyperkalemia risk must be managed. Finerenone effectively reduces CKD and cardiovascular risks in type 2 diabetes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, FIDELIO-DKD Investigators

Citation: Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England journal of medicine. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →